Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS -Mutant NSCLC.

Autor: Aredo JV; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Ramchandran KJ; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Neal JW; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Diehn M; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hui AB; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Salahudeen A; Department of Internal Medicine, University of Illinois Cancer Center, Chicago, Illinois., Kwong B; Department of Dermatology, Stanford University School of Medicine, Stanford, California., Berry GJ; Department of Pathology, Stanford University School of Medicine, Stanford, California., Guo HH; Department of Radiology, Stanford University School of Medicine, Stanford, California., Cunanan K; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California., Vali S; Cellworks Group, South San Francisco, California (Prior)., Pancirer D; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Tsang V; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hwang G; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Loza M; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Johnson B; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Blanchard I; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Padda SK; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Hematology/Oncology, Fox Chase Cancer Center/Temple Health, Philadelphia, Pennsylvania.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2024 Oct 17; Vol. 5 (12), pp. 100741. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024).

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Autor: Chen ST; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Mass General Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Semenov YR; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Alloo A; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA., Bach DQ; Department of Dermatology, Cedars Sinai, Los Angeles, California, USA., Betof Warner A; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Bougrine A; Department of Dermatology, Université de Montréal, Montreal, Quebec, Canada., Burton L; Biogen Inc, Cambridge, Massachusetts, USA., Cappelli LC; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Castells M; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Cohen J; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Centers for Cutaneous and Melanoma Oncology, Dana-Farber Cancer Insititute, Boston, MA, USA., Dewan AK; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Fadden R; Mass General Cancer Center, Boston, MA, USA., Guggina L; Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hegde A; UAB, Birmingham, Alabama, USA., Huang V; Department of Dermatology, University of California Davis, Davis, California, USA., Johnson DB; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Kaffenberger B; Department of Dermatology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Kroshinsky D; Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA., Kwatra S; Johns Hopkins Department of Dermatology, Baltimore, Maryland, USA., Kwong B; Stanford University School of Medicine, Stanford, UK., Lacouture ME; MSKCC, New York, New York, USA.; NYU Langone Health, New York, New York, USA., Larocca C; Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leventhal J; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA., Markova A; Memorial Sloan Kettering Cancer Center, New York, New York, USA., McDunn J; Project Data Sphere ®, Morrisville, North Carolina, USA., Mooradian MJ; Mass General Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Naidoo J; Johns Hopkins University, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA., Choi J; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Nambudiri V; Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nelson CA; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA., Patel AB; Department of Dermatology, Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pimkina J; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Rine J; Project Data Sphere ®, Morrisville, North Carolina, USA., Rubin KM; Mass General Cancer Center, Boston, MA, USA., Sauder M; DIvision of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Shaigany S; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA., Shariff A; Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Sullivan RJ; Mass General Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., Zubiri L; Mass General Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., Reynolds KL; Mass General Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., LeBoeuf NR; Harvard Medical School, Boston, Massachusetts, USA nleboeuf@bwh.harvard.edu.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 10; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 10.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases.

Autor: Collins JC; Stem Cell Biochemistry Unit, National Institute of Dental and Craniofacial Research, National institutes of Health, Bethesda, MD., Magaziner SJ; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY., English M; Stem Cell Biochemistry Unit, National Institute of Dental and Craniofacial Research, National institutes of Health, Bethesda, MD., Hassan B; Protein Processing Section, Center for Structural Biology, National Cancer Institute, National Institutes of Health, Frederick, MD., Chen X; Protein Processing Section, Center for Structural Biology, National Cancer Institute, National Institutes of Health, Frederick, MD., Balanda N; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY., Anderson M; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY., Lam A; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY., Fernandez-Pol S; Department of Pathology, Stanford University Medical School, Stanford, California, USA., Kwong B; Department of Dermatology, Stanford University Cancer Center, Stanford, CA, USA., Greenberg PL; Division of Hematology, Stanford University Cancer Center, Stanford, California, USA., Terrier B; Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris., Likhite ME; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY., Kosmider O; Laboratory of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris., Wang Y; Mass Spectrometry Facility, National Institute of Dental and Craniofacial Research, National institutes of Health, Bethesda, MD., Samara NL; Structural Biochemistry Unit, National Institute of Dental and Craniofacial Research, National institutes of Health, Bethesda, MD., Walters KJ; Protein Processing Section, Center for Structural Biology, National Cancer Institute, National Institutes of Health, Frederick, MD., Beck DB; Center for Human Genetics and Genomics, New York University School of Medicine, New York, NY.; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY.; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY., Werner A; Stem Cell Biochemistry Unit, National Institute of Dental and Craniofacial Research, National institutes of Health, Bethesda, MD.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Oct 10. Date of Electronic Publication: 2023 Oct 10.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.